

The Global Impact of COVID-19 on Tuberculosis: A Thematic Scoping Review, 2020-2023

(Running Title: Global Impact of COVID-19 on TB)

Michael H. Marco, PhD, MPH;¹ Sevim Ahmedov, MD, MPA;¹ and Kenneth G. Castro, MD^{1,2}

Keywords: Tuberculosis, TB, SARS-CoV-2, COVID-19, pandemic, healthcare, health systems

Author Affiliations:

1. TB Division, Office of Infectious Diseases, Bureau for Global Health, United States Agency for International Development, Washington, DC, USA
2. Rollins School of Public Health, School of Medicine, Emory TB Center, Emory University, Atlanta, GA, USA

Corresponding Author:

Michael H. Marco, PhD, MPH
TB Division, Office of Infectious
Diseases, Bureau for Global Health,
United States Agency for International
Development, 500 D Street SW,
Washington, DC 20547, USA; email,
mhm2109@gmail.com

Author Contributions: Conceptualization, KGC, and MHM; developing and conducting the search strategy, MHM, KGC, and SA; screening, MHM, KGC, and SA; writing original draft, MHM; writing, reviewing, and editing, KGC, SA, MHM; supervision, KGC. All authors have read and agreed to a published version of the manuscript.

Role of Funding:

United States Agency for International Development

Disclosures:

None

Abstract

Background: This thematic scoping review of publications sought to understand the global impact of COVID-19 on tuberculosis (TB), interpret the scope of resonating themes, and offer policy recommendations to stimulate TB recovery and future pandemic preparedness.

45 **Data Sources:** Publications were captured from three search engines, PubMed, EBSCO, and
46 Google Scholar, and applicable websites written in English from January 1, 2020, to April 30,
47 2023.

48
49 **Study Selection:** Our scoping review was limited to publications detailing the impact of COVID-
50 19 on TB. Original research, reviews, letters, and editorials describing the deleterious and
51 harmful—yet sometimes positive— impact of COVID-19 (sole exposure) on TB (sole outcome)
52 were included. The objective was to methodically categorize the impacts into themes through a
53 comprehensive review of selected studies to provide significant health policy guidance.

54
55 **Data Extraction:** Two authors independently screened citations and full texts, while the third
56 arbitrated when consensus was not met. All three performed data extraction.

57
58 **Data Synthesis/Results:** Of 1,755 screened publications, 176 (10%) covering 39 countries over
59 41 months met the inclusion criteria. Ten principal themes were established, which
60 encompassed TB's care cascade, patient-centered care, psychosocial issues, and health
61 services: 1) case-finding and notification (n=45; 26%); 2) diagnosis and laboratory systems
62 (n=19; 10.7%) 3) prevention, treatment, and care (n=22; 12.2%); 4) telemedicine/telehealth
63 (n=12; 6.8%); 5) social determinants of health (n=14; 8%); 6) airborne infection prevention and
64 control (n=8; 4.6%); 7) health system strengthening (n=22; 13%); 8) mental health (n=13; 7.4%);
65 9) stigma (n=11; 6.3%); and 10) health education (n=10; 5.7%).

66

67 **Limitations:** Heterogeneity of publications within themes.

68

69 **Conclusions:** We identified ten globally generalizable themes of COVID-19’s impact on TB.

70 These thematic areas will guide evidence-informed policies to strengthen comprehensive global
71 responses, recovery for TB, and future airborne pandemic preparedness.

72

73 **Primary Funding Source:** United States Agency for International Development

74

75 **BACKGROUND**

76 Before the first COVID-19 cases were reported in Wuhan, China, in late 2019 [1-2] and the
77 World Health Organization’s (WHO) declaration of COVID-19 as a global pandemic on March 11,
78 2020 [3], tuberculosis (TB) was the world’s leading cause of death from a single infectious
79 disease, causing 1.4 million deaths in 2019 [4]. Global TB deaths declined by 35% between 2009
80 and 2019, due in part to Member State commitments to WHO’s 2015 “End TB Strategy” [5] and
81 the 2018 United Nations High-Level Meeting declaration to end the TB epidemic [6].

82

83 The global spread of COVID-19 likely derailed the promise of and trajectory for ending TB in this
84 decade. COVID-19 wiped out over 12 years of hard-fought gains, such as increased TB
85 detections and decreased TB-related mortality [7]. The initial marked drop in the reported
86 number of newly diagnosed TB cases dropped from a peak of 7.1 million in 2019 to 5.8 million
87 in 2020—a decline of 18% [8]. It is estimated that there will be 4,702,800 TB cases and an
88 additional 1,044,800 TB deaths worldwide between 2020 and 2025 due to the disruptions in TB

89 detection and treatment during lockdowns, and the prioritization of COVID-19 services [9]. By
90 2022, the WHO [10] stated, "...the COVID-19 pandemic continues to have a damaging impact on
91 access to TB diagnosis and treatment and the burden of TB disease."

92
93 We conducted a scoping review to explore the impact, effect, and aftermath of COVID-19 on all
94 aspects of TB, from the clinical cascade to patient-centered care, provision, and psychosocial
95 issues. Based on our analysis, we identified ten principal themes and expanded the traditional
96 model of a scoping review by offering policy recommendations aligned with these principal
97 themes. This review and discussion target policymakers. As COVID-19 continues to cause
98 morbidity and mortality, and the threat of future airborne infection pandemics remains a real
99 possibility, it seemed prudent to offer TB policy recommendations to global and national
100 leaders to build and maintain a robust TB infrastructure with surge capacity for response,
101 recovery, and resilience.

102

103 **METHODS**

104 The analysis of publications and grey literature was conducted to identify and define resonating
105 themes of COVID-19's global impact on TB and inform policy recommendations to assist in TB
106 resilience, recovery, and future pandemic preparedness. This scoping review was conducted in
107 accordance with PRISMA Extension for Scoping Reviews guidelines and Joanna Briggs Institute
108 (JBI) methodology [11-12] (Appendix 1, JBI Protocol, and published at DOI:
109 <https://doi.org/10.6084/m9.figshare.24566842.v1>; Appendix 2, "Checklist")

110

111 **Data Sources and Searches**

112 We included qualitative and quantitative original research, case series, letters to the editor,
113 editorials, and review articles that met the inclusion criteria. On May 1, 2023, publications
114 written in English were captured from three search engines: PubMed, EBSCO, Google Scholar,
115 and global health multilateral websites from January 1, 2020, to April 30, 2023. The PubMed
116 search terms, which originated from the consensus in review team meetings, were:
117 *((Mycobacterium tuberculosis or tuberculosis or TB [MeSH Terms])) AND ((COVID-19 or COVID*
118 *or pandemic COVID-19 or coronavirus or sars-cov-2 [MeSH Terms])) AND ((primary healthcare*
119 *or health services or healthcare system [MeSH Terms]))*. (See Appendix 1a: “Search Strategy”
120 for the search terms employed for EBSCO and Google Scholar.)

121
122 This search strategy was designed to be wide-ranging and purposeful to include as many studies
123 as possible from low- and middle-income countries (LMIC). Identified citations were uploaded to
124 EndNote™ 20 (Clarivate™) and transferred to COVIDENCE systematic review software for
125 screening.

126

127 **Study Selection**

128 The Population, Concept, and Context (PCC) framework [11] was applied to assist the review
129 team in setting eligibility criteria. The inclusion criteria stipulated that the literature must
130 discuss COVID-19 (the sole exposure) as the impact, effect, or consequence of any aspect of TB
131 (the sole outcome). Letters to the editor and editorials were required to contain original data or
132 substantive recommendations. We excluded 1) published abstracts; 2) magazines; 3) online

133 pre-publications that were never published; and 4) literature focusing on the clinical sequelae
134 of COVID-19 and TB co-infection, or co-infection dynamics between TB and COVID-19 with
135 other illnesses (e.g., HIV, diabetes).

136
137 MHM and KGC conducted independent screening of titles and abstracts; when disagreement
138 occurred, SA adjudicated. MHM and KGC conducted independent full-text reviews with SA,
139 confirming ineligible publications.

140

141 ***Data Extraction and Quality Assessment***

142 Data were extracted independently by the three authors using a data extraction tool developed
143 by the review team (Appendix 1b; Table 1). Descriptive variables extracted included author(s),
144 geography, publication year, publication type, and perceived themes.

145

146 ***Data Synthesis and Analysis***

147 Determining the resonating themes of publications and how many were decided by consensus.
148 Analysis of a publication's sub-themes was essential for proper categorization. While a
149 publication's title/topic pointed to a specific theme (e.g., case-finding and notification), there
150 were instances when it was added to a different theme because of substantial, pertinent
151 discussions on additional underlying causes or solutions. Themes and their respective
152 publications were presented in tabular form (Appendix 3) with a narrative summary describing
153 how each related to COVID-19's global impact on TB.

154

155 ***Role of the Funding Source***

156 This work was funded by the United States Agency for International Development.

157

158 **RESULTS**

159 Figure 1 describes the selection process for publication. Three search engines identified 1,755
160 publications: PubMed (n=701), EBSCO (n=105), and Google Scholar (n=701). Through citation
161 searching, 35 additional publications were captured; 4 were grey literature. There were 114
162 duplicate titles, leaving 1,674 publications for title and abstract screening. There was
163 agreement from MHM and KGC that 1,426 were irrelevant—i.e., not meeting inclusion criteria—
164 —with a discrepancy of 33. SA adjudicated, characterizing all 33 irrelevant, leaving 1,459
165 discarded and 217 publications moving to full-text review. Of the full texts reviewed by MHM
166 and KGC, 41 were ineligible, with confirmation by SA. Thus, 176 publications went forward for
167 data capturing and analysis.

168

169 **Figure 1. Scoping Review Schema** **Courtesy of COVIDENCE**

170

171 In our analyses of 176 publications from 39 countries covering 41 months, ten principal themes
172 (as depicted in Figure 2) were identified characterizing the breadth of the global impact of
173 COVID-19 on TB: 1) case-finding and notification (n=45; 26%); 2) diagnosis and laboratory
174 systems (n=19; 10.7%); 3) prevention, treatment, and care (n=22; 12.2%); 4)
175 telemedicine/telehealth (n=12; 6.8%); 5) social determinants of health (n=14; 8%); 6) airborne

176 infection prevention and control (n=8; 4.6%); 7) health system strengthening (n=22; 13%); 8)
177 mental health (n=13; 7.4%); 9) stigma (n=11; 6.3%); and 10) health education (n=10; 5.7%).

178

179 **Figure 2. Ten Themes Characterizing the Global Impact of COVID-19 on TB**

180

181 ***Case-Finding and Notifications***

182 A quarter of the publications (n=45) from over 20 countries [7, 9, 13-55] addressed the
183 deleterious impact of COVID-19 on active TB case-finding, notification, and contact tracing
184 during multiple lockdowns and restrictions. Globally, TB case-finding and notification decreased
185 by an estimated 18% between 2019 and 2020 [8], yet resilient TB programs initiated measures
186 to address this drop-off when community health workers (CHWs) were overwhelmed by COVID-
187 19 testing and response activities. A retrospective data analysis of the impact of COVID-19 on
188 TB case notification and other indicators from Migliori et al. [39] covered five continents and
189 drew data from 43 TB centers in 19 countries. TB case notification decreased from 32,898 in
190 2019 to 16,396 in 2020; the most precipitous decline occurred in March 2020. Only two
191 counties, Australia, and Singapore, and one state (Virginia, in the U.S.) did not report decreases.

192

193 To help blunt the precipitous global decline in TB case notification, finding, and detection, Sahu,
194 et al. [7] stressed the urgency of resilience and recovery from COVID-19 by fast-tracking the
195 2018 United Nations General Assembly High-Level Meeting TB targets [6] and aligning
196 vaccination services with active early case finding and other community-based TB services.

197

198 Publications from several countries described the diversion of resources from TB to COVID-19
199 and how multiple lockdowns during the pandemic negatively impacted active case-finding and
200 contact investigations, markedly decreasing the detection of people with TB disease or TB
201 infection [7, 15, 17, 26, 30, 43, 52-55]. A few publications [7, 17, 53-55] acknowledged that
202 digital tools developed and deployed for COVID-19 contact tracing could help facilitate future
203 TB contact investigations. Pai, et al. [54] described the need for targeted active case-finding
204 initiatives employing portable digital X-ray systems with artificial intelligence (AI) software.
205 Ruhwald, et al. [53] asserted that the novel use of COVID-19 molecular technologies and bi-
206 directional testing will benefit TB diagnosis and reduce reliance on suboptimal tools, such as
207 smear microscopy. Sahu, et al. [7] asserted that these advanced diagnostics must be readily
208 implemented in the community to meet people where they live. Finally, Chan, et al. [17]
209 highlighted the benefits and risks of using molecular technology in the community.

210

211 ***Diagnosis and Laboratory Systems***

212 Nineteen publications [56-74] focused on COVID-19's detrimental impacts on TB diagnosis,
213 laboratory capacity and systems, and the supply chain.

214

215 Mauer, et al. (73) detailed a WHO survey of 31 national TB reference laboratories in the
216 European Union and the United Kingdom, reporting that COVID-19-related disruptions to TB
217 laboratory services peaked from March to June 2020. The core laboratory setbacks were: 1)
218 sample turnaround time; 2) access to external quality assessment; and 3) availability of
219 diagnostic services.

220 Tovar, et al. [72] conducted a modelling analysis to determine the impact of COVID-19 setbacks
221 in TB diagnostic and laboratory services on patient mortality in India, Indonesia, Kenya, and
222 Pakistan in 2022. They calculated that stark, pandemic-related reductions in new TB diagnoses
223 could result in 378,000 excess deaths across the four countries.

224
225 Integrating COVID-19 and TB testing was proposed by MacLean, et al. [63] as a solution to
226 identify and diagnose more people with TB disease. They contended that during the pandemic,
227 too many people refrained from accessing healthcare, including essential TB testing. They
228 provided integrated testing recommendations for 1) urban settings with the highest TB
229 prevalence and those vulnerable to COVID-19; 2) rural settings in high-burden countries to
230 improve the quality of patient care; and 3) countries with high HIV prevalence.

231
232 In 2020, Aswathi and Singh [74] provided solutions for India's TB diagnostic and laboratory
233 obstacles. They called for the Indian government to increase testing by arranging additional
234 machines and increasing the number of shifts for laboratory testing. Furthermore, they called
235 for the Government's TB Program to offer upfront TB testing with GeneXpert® or Truenat®
236 instead of smear microscopy.

237

238 ***Prevention, Treatment, and Care***

239 Twenty-two publications [75-96] centered on the pandemic's negative impact on TB
240 prevention, treatment, and care in diverse patient populations; some proposed measures to
241 optimize TB treatment.

242 In a 2023 rapid review from South Korea, Jeong et al. [83] reported that global detection and
243 treatment of TB infection were among the most negatively impacted steps in the TB cascade
244 across low-, middle-, and high-income countries (LMHC). Two retrospective data analyses
245 comparing TB preventive treatment initiation before and during the pandemic reported a
246 44.7% decline in Addis, Ethiopia [76] and 30% and 66% in Montreal and Toronto, Canada [77],
247 respectively.

248

249 The pandemic resulted in global stockouts of BCG vaccine for infants [89, 94]. Namkoong, et al.
250 [89] hypothesized that the vaccine shortage was partly caused by WHO's supplier withdrawal
251 due to production issues, which left UNICEF [97] with a 30% decrease in supply. Another
252 explanation was the renewed interest in basic science research [98] that supported BCG's
253 enhancement of immune responses. This led to off-label use, even after the publication of
254 results from a failed efficacy trial of BCG for COVID-19 prevention [99].

255

256 Arega et al. [76] conducted a retrospective data analysis of TB treatment outcomes in Ethiopia,
257 finding that the TB treatment success rate decreased by 17% between March 2019 and March
258 2020 and that rifampicin resistance (RR) increased by 27.7%.

259

260 The increase of RR/multidrug-resistant (MDR) TB was observed in different settings during the
261 pandemic. From the proceedings of the National Academies of Sciences workshop, "Innovations
262 for Tackling Tuberculosis in the Time of COVID-19," Salmaan Keshavjee [90] underscored the

263 necessity of continuing TB treatment during the pandemic by administering the most tolerable
264 and shortest DS-TB, and all-oral DR TB regimens, and promoting treatment adherence.

265

266 ***Telemedicine/Telehealth***

267 Twelve publications [100-111] discussed how LMIC swiftly implemented telehealth
268 interventions to offset COVID-19 disruptions in TB services. Various digital tools enabled virtual
269 case identification, TB care, treatment, and adherence [4].

270

271 A rapid assessment of telemedicine’s potential to optimize TB care and treatment was
272 conducted by Klinton et al. [102] during March – December 2020 in seven high-burden
273 countries. The interventions included telemedicine/telehealth platforms (e.g., text messages,
274 phone, and video) enabling consultations, video-observed therapy (VOT) for adherence, refill
275 reminders, and novel diagnostic platforms such as AI-based and portable digital chest X-rays.
276 Researchers noted that digital tools could strengthen the diagnostic capacity of TB programs,
277 enhance patient-centered care, decentralize TB services, and contribute towards progress in
278 achieving the EndTB goals.

279

280 Calnan, et al. [107] described a phone-based TB case-finding and case-management
281 intervention launched in two regions of the Philippines between October 2020 and September
282 2021. Fourteen TB contact centers conducted TB screening and contact investigation and
283 provided information about testing, delivery of test results, and adherence support. Call centers
284 identified 9.2% of people with TB in the region, of which 43.5% (827/1,901) initiated treatment.

285 A cost-benefit analysis compared the new telehealth service versus standard-of-care (SOC)
286 case-finding interventions found that the 1-year cost for implementing call centers totaled USD
287 557 per patient, only USD 7.00 more than SOC.

288
289 A 197-person study by Visca, et al. (108) compared the effectiveness and cost of VOT versus
290 clinic-based directly observed therapy (DOT) in Moldova. They found that VOT significantly
291 improved adherence (1.29 missed days versus 5.24 missed days) over two weeks spent on clinic
292 transport among VOT patients by 58 hours.

293

294 ***Social Determinants of Health***

295 Fourteen publications [112-125] addressed social determinants of health (SDH) and COVID-19's
296 outsized effect on vulnerable populations and offered solutions to mitigate them. Singh et al.
297 [112] summarized the contribution of SDH to an additional 700,000 undiagnosed and missing
298 active TB cases in Southeast Asia between 2019 and 2020, noting that the pandemic adversely
299 impacted the nutritional status and BMI of the affected populations, which, in turn, was likely
300 to have contributed to secondary immunodeficiency and an influx of undiagnosed TB cases.

301

302 In a 2020 editorial, Saunders et al. [115] proposed social protection interventions—"safety
303 nets"—for vulnerable populations, noting that impoverished, at-risk TB populations could not
304 work and access funds to provide social protection during lockdowns. They recommended
305 special provisions, including cash transfers or food parcels for TB-affected households. Notably,

306 they called for psychosocial support for affected households and access to digital technology to
307 improve equity and access to virtual care during lockdowns.

308
309 In Brazil, Souza, et al. [123] surveyed healthcare workers about the surge in MDR TB during the
310 first two waves of COVID-19, documenting an association between MDR TB cases and SDH (e.g.,
311 poverty, vulnerability, and social risk). Weakened adherence was associated with cuts in social
312 protection and benefits.

313

314 ***Airborne Infection Prevention and Control***

315 Eight publications [126-133] addressed airborne infection prevention and control and personal
316 protective equipment (PPE) for healthcare workers and people with TB.

317

318 Mannan et al. [126] from Joint Effort for Elimination of TB (JEET) in India, a nationwide Global
319 Fund project across 406 districts in 23 states, surveyed 21,750 physicians between February
320 and March 2021. Many survey questions examined infection prevention and control measures
321 (IPC) implemented in their clinics due to COVID-19. Approximately 82% of surveyed providers
322 employed social distancing and increased the interval between patients' appointments. While
323 70% reported knowledge that IPC measures could decrease TB transmission, 62% initiated PPE
324 use, and only 13% physically implemented physical changes (e.g., air filters and isolation of
325 patient areas).

326

327 To prevent airborne infections in TB diagnostic and treatment centers, Awan, et al. [127]
328 proposed several measures at clinics: building and maintaining sizeable outdoor patient waiting
329 areas, installing ventilation and air circulation exhaust systems in clinics, ultraviolet germicidal
330 irradiation lights, and designated sputum expectoration areas.

331 The shortage of PPE during COVID-19 was echoed in multiple publications from various
332 countries [129-131]. Jain and colleagues [130] reviewed literature published in India in May
333 2020, which underscored complaints about the paucity of PPE, noting that this made it
334 impossible for HCWs to provide safe, regular healthcare services for people with TB. Moreover,
335 healthcare workers were fearful and reluctant to take samples from people with TB due to a
336 lack of appropriate PPE.

337

338 ***Health System Strengthening***

339 National TB Programs (NTP) in many LMICs were hobbled and underperformed well before the
340 advent of COVID-19. The pandemic imposed an unprecedented burden, leaving programs and
341 services faltering. Twenty publications examined the need for health system strengthening
342 (HSS) [134-155].

343

344 Khan, et al. [139] cited NTP data on widespread disruptions across the care cascade in Pakistan
345 during 2020 due to limited and dwindling resources. Between March 1 and June 30, 2020,
346 GeneXpert® machines and hospital isolation wards were re-directed from TB to COVID-19,
347 delayed TB diagnoses. Meanwhile, outpatient TB visits dropped by 59.55%, and hospitalizations

348 declined by 50.7%, increasing the risk of household transmission. Due to staffing shortages, TB
349 treatment was often interrupted, and follow-up visits were delayed or canceled.

350
351 Some publications addressed TB differentiated service delivery (DSD) as an essential facet of
352 strengthening health systems [148, 150, 153-154]. DSD models (such as multi-month
353 dispensing, pickup points for or home delivery of medications, and VOT) quickly emerged,
354 allowing TB services to continue outside the clinic during lockdowns. While piecemeal DSD
355 models for TB were rolled out in the past, these were developed and deployed in an expansive,
356 global, warp-speed offensive during the pandemic [101, 104, 146].

357
358 Klinton et al. [142] observed a silver lining for TB HSS, noting global resilience, recovery, and
359 innovative improvements despite the erosion of TB services during the pandemic. The private
360 sector enabled the rapid deployment of innovations that improved TB services and health
361 systems, demonstrating resilience by adapting guidelines, policies, and digital tools to improve
362 accessibility, acceptability, and quality of TB prevention, care, and treatment. The pandemic
363 experience highlighted the importance of strengthening and adapting TB health system
364 services, and the essential role of public-private partnerships in maintaining them. These
365 observed benefits strengthened overall health systems well beyond TB services.

366

367 ***Mental Health***

368 Depression is more prevalent among people with TB than in the general population. A 2020
369 systematic review and meta-analysis by Ruiz-Grosso, et al. [156] documented a strong

370 association between TB and depression that caused adverse TB treatment outcomes, including
371 poor adherence, loss-to-follow-up, and death. Thirteen publications [157-169] discussed mental
372 health concerns, emphasizing the escalation of fear and anxiety among people with TB during
373 the pandemic.

374 Loveday, et al. [157] noted that lockdowns and other COVID-19 restrictions in South Africa
375 posed harsh financial consequences for people who were already economically vulnerable,
376 contributing to anxiety, stress, and depression among people with TB.

377 Pronounced fear and anxiety were evident in an 842-person global survey [162] coordinated by
378 nine TB non-governmental organizations (NGOs). Qualitative and quantitative data were
379 collected from people with TB and survivors, healthcare workers, NTP staff, civil society, and
380 advocates between May 26, 2020, and July 2, 2020. Over half of the people with TB reported
381 feeling increased vulnerability to and fear of contracting COVID-19, which prevented some of
382 them from seeking treatment. This study and others [154-157] mentioned that healthcare
383 workers feared seeing patients because of anxiety about acquiring COVID-19 and transmitting it
384 to their families.

385 During the pandemic, a novel telehealth approach to assess mental health among people with
386 TB and healthcare providers was implemented in Pakistan [159]. Through regular phone calls,
387 mental health providers checked emotional well-being and screened people for depression and
388 anxiety. Additional support was provided for those who acquired COVID-19.

389

390 ***Stigma***

391 Eleven publications [170-180] addressed TB-related stigma, the populations most affected, and
392 its adverse effects—especially during COVID-19—and solutions to combat it.

393

394 Dheda et al. [180] shared their frank views of TB-related stigma in a 2022 commentary. They
395 asserted that “social stigma kills,” noting that it is repugnant for people who battle airborne
396 infectious diseases in isolation to fight social stigma simultaneously.

397

398 Mahnoor Islam [173] wrote that TB-related stigma during the height pandemic led to poor
399 treatment outcomes. He asserted that the stigma of respiratory symptoms faced by people
400 with TB, which COVID-19 often compounded, led to a reluctance to visit healthcare facilities,
401 thus enabling drug resistance because of incomplete therapy.

402

403 Anti-stigma interventions must be specifically tailored to patient groups (e.g., women and girls)
404 in different countries. In a commentary on COVID-19 and TB in Pakistan, Fatima et al. [172]
405 asserted that the best way to alleviate the stigma of TB for women and girls is to develop and
406 employ TB interventions in rural communities with the aid and expertise of lady health workers.

407

408 ***Health Education***

409 Ten publications [181-190] addressed the need for TB patient education programs and
410 community information campaigns to assuage fear, anxiety, and stigmatization, which leads
411 those with TB—and undiagnosed people—to avoid clinics for fear of COVID-19. Likewise,

412 educating TB healthcare workers about COVID-19 and how to reduce their risk is essential for
413 them to feel safe and continue working.

414
415 An Iranian qualitative study by Shahnavaizi, et al. [190] discussed the reduction in time HCWs
416 had for patient education and follow-up instructions during the pandemic. HCW disclosed that
417 they only had enough time to dispense TB medication before abruptly leaving to attend to
418 COVID-19 duties.

419
420 In 2021, Nkereuwem, et al. [181] surveyed European and West African healthcare workers in
421 2021. Many of the respondents underscored the importance of intensified health education.
422 One respondent said TB education campaigns can help remind the world “not to forget TB” and
423 make people aware that a chronic cough may not be from COVID-19. Another respondent
424 decreed that there must be more public education on TB because COVID-19 overshadowed
425 messaging about other diseases. Some urged NTPs to offer timely statements and guidance on
426 routine TB screening, diagnosis, and treatment during COVID-19 and future pandemics.

427
428 Chapman et al. [182] noted that digital health interventions exist to transform TB care by
429 disseminating essential health information that supports treatment adherence and encourages
430 health-seeking behaviors among people with TB. They addressed the need for public health
431 communication campaigns to combat the “infodemic,” which they defined as “the rapid spread
432 of false information on TB and COVID-19.”

433

434 **DISCUSSION**

435

436 This comprehensive scoping review assessed the global impact of COVID-19 on TB. It covers the
437 most prolonged publication period (41 months [January 1, 2000 – April 30, 2023]) and the most
438 significant number of publications analyzed (n=176) from 39 countries. The timespan includes
439 publications with data and perspectives from multiple pandemic waves—the COVID-19 Wuhan-
440 Hu-1, Delta, and Omicron variants.

441

442 This scoping review sought to be inclusive of publications from LMIC in an effort to add to prior
443 publications from high-income countries. By casting a wide net, we were able to detail the
444 diversity of complex TB issues and conditions faced globally by many countries, cultures, and
445 patient populations during the pandemic. The analysis of 176 publications yielded ten key
446 themes, categorized into areas such as the tuberculosis care cascade, patient-centered
447 care, and psychosocial issues. Many publications, mainly reviews and editorials, had
448 overlapping themes.

449

450 Several publications, across all themes, offered recommendations for combatting a wide range
451 of TB issues [7, 54, 74, 83, 90, 108, 117, 127, 137, 139, 142, 153, 157, 172, 174, 180-181]. Some
452 recommendations took a “glass half-full” approach by addressing the potential for positive,
453 post-pandemic impacts on TB—leveraging and retrofitting aspects of the pandemic response,
454 such as new developments in case-finding, diagnostics, and health education.

455 There are limitations in our scoping review. Some letters to the editors, which were included
456 due to an a priori requirement that original data be discussed, risked the inclusion of data not
457 validated for accuracy. We also detected heterogeneity of publications within themes.

458

459 This all-inclusive scoping review established that, despite geographic and income-level
460 heterogeneity, there are several generalizable themes between countries on the impact of
461 COVID-19 on TB. The intensity and magnitude of illness and death from COVID-19 in 2020
462 rapidly overwhelmed TB programs. Consequently, the TB infrastructure and workforce were
463 repurposed for the COVID-19 response. It will take time for TB programmatic aspects to fully
464 recover and regain a sense of normalcy and productivity.

465

466 The most recent 2023 United Nations General Assembly High-Level Meeting on TB included
467 commitments to universal health coverage, pandemic prevention, preparedness, and response,
468 and the fight against TB, underscoring the crucial need to simultaneously strengthen and
469 address urgent realities and serious threats [191, 192]. The ten themes identified through this
470 scoping review provide a framework for comprehensive progress by TB programs to
471 simultaneously achieve the End TB goal and address future airborne disease pandemics.

472

473 **ACKNOWLEDGMENTS**

474

475 We thank Cheri Vincent, Tara Ornstein, Amy Bloom, and YaDiul Mukadi for discussions
476 regarding

477

478 the scope of the review and assistance in developing the search string; Tracy Swan for editorial

479

480 assistance; David Pieribone for graphic assistance with Figure 2; Marcus Renick for graphic

481
482 assistance with the appendices, and COVIDENCE for offering complimentary software use.

483
484
485

486 REFERENCES

487
488

- 489 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel
490 coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506. doi: 10.1016/s0140-6736(20)30183-5.
- 491 2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in
492 China, 2019. *N Engl J Med*. 2020;382(8):727-33. doi: 10.1056/NEJMoa2001017.
- 493 3. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 -
494 11 March 2020. Available from: [https://www.who.int/director-general/speeches/detail/who-director-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
495 [general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
- 496 4. World Health Organization. Global Tuberculosis Report 2020. Available from:
497 <https://www.who.int/publications/i/item/9789240013131>
- 498 5. World Health Organization. The End TB Strategy. Available from:
499 <https://iris.who.int/bitstream/handle/10665/331326/WHO-HTM-TB-2015.19-eng.pdf?sequence=166>.
- 500 6. United Nations General Assembly Resolution A/RES/73/3. Political declaration of the high-level meeting of
501 the General Assembly on the fight against tuberculosis. Recovering from the Impact of the Covid-19
502 Pandemic and Accelerating to Achieving the United Nations General Assembly Tuberculosis Targets,
503 October 2018. Washington, DC. Available from: <https://www.undocs.org/en/A/RES/73/3>
- 504 7. Sahu S, Ditiu L, Sachdeva KS, Zumla A. Recovering from the Impact of the Covid-19 Pandemic and
505 Accelerating to Achieving the United Nations General Assembly Tuberculosis Targets. *Int J Infect Dis*.
506 2021;113 Suppl 1:S100-3. doi: 10.1016/j.ijid.2021.02.078.
- 507 8. World Health Organization. Global Tuberculosis Report 2021. Available from:
508 <https://www.who.int/publications/i/item/9789240037021>

- 509 9. Cilloni L, Fu H, Vesga JF, Dowdy D, Pretorius C, Ahmedov S, et al. The potential impact of the COVID-19
510 pandemic on the tuberculosis epidemic a modelling analysis. *EClinicalMedicine*. 2020;28:100603. doi:
511 10.1016/j.eclinm.2020.100603.
- 512 10. World Health Organization. Global Tuberculosis Report 2022. Available from:
513 <https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022>
- 514 11. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews
515 (PRISMA-ScR): checklist and explanation. *Ann Intern Med*. 2018;169(7):467-73. doi: 10.7326/m18-0850.
- 516 12. Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance
517 for the conduct of scoping reviews. *JBI Evid Implementation*. 2021;19(1):3-10. doi:
518 10.1097/xeb.0000000000000277.
- 519 13. Alene KA, Wangdi K, Clements ACA. Impact of the COVID-19 pandemic on tuberculosis control: An
520 Overview. *Trop Med Infect Dis*. 2020;5(3):123. doi: 10.3390/tropicalmed5030123.
- 521 14. Arentz M, Ma J, Zheng P, Vos T, Murray CJL, Kyu HH. The impact of the COVID-19 pandemic and
522 associated suppression measures on the burden of tuberculosis in India. *BMC Infect Dis*. 2022;22(1):92.
523 doi: 10.1186/s12879-022-07078-y.
- 524 15. Aznar ML, Espinosa-Pereiro J, Saborit N, Jové N, Sánchez Martínez F, Pérez-Recio S, et al. Impact of the
525 COVID-19 pandemic on tuberculosis management in Spain. *Int J Infect Dis*. 2021;108:300-5. doi:
526 10.1016/j.ijid.2021.04.075.
- 527 16. Bhargava A, Bhargava M, Meher A. Universal health coverage and tuberculosis care in India in the times of
528 Covid-19: Aligning Ayushman Bharat (National Health Assurance Scheme) to improve case detection,
529 reduce deaths and catastrophic health expenditure. *Natl Med J India*. 2020;33(5):298-301. doi:
530 10.4103/0970-258x.303111.
- 531 17. Chan G, Triasih R, Nababan B, du Cros P, Wilks N, Main S, et al. Adapting active case-finding for TB during
532 the COVID-19 pandemic in Yogyakarta, Indonesia. *Public Health Action*. 2021;11(2):41-9. doi:
533 10.5588/pha.20.0071.
- 534 18. Choi H, Ko Y, Lee CY, Chung SJ, Kim HI, Kim JH, et al. Impact of COVID-19 on TB epidemiology in South
535 Korea. *Int J Tuberc Lung Dis*. 2021;25(10):854-60. doi: 10.5588/ijtld.21.0255.

- 536 19. Crowder R, Geocaniga-Gaviola DM, Fabella RA, Lim A, Lopez E, Kadota JL, et al. Impact of shelter-in-place
537 orders on TB case notifications and mortality in the Philippines during the COVID-19 pandemic. *J Clin*
538 *Tuberc Other Mycobact Dis.* 2021;25:100282. doi: 10.1016/j.jctube.2021.100282.
- 539 20. Datta B, Jaiswal A, Goyal P, Prakash A, Tripathy JP, Trehan N. The untimely demise of the TB Free block
540 model in the wake of coronavirus disease 2019 in India. *Trans R Soc Trop Med Hyg.* 2020;114(11):789-91.
541 doi: 10.1093/trstmh/traa067.
- 542 21. de Souza CDF, Coutinho HS, Costa MM, Magalhaes M, Carmo RF. Impact of COVID-19 on TB diagnosis in
543 Northeastern Brazil. *Int J Tuberc Lung Dis.* 2020;24(11):1220-2. doi: 10.5588/ijtld.20.0661.
- 544 22. Ding W, Li Y, Bai Y, Li Y, Wang L, Wang Y. Estimating the effects of the COVID-19 outbreak on the
545 reductions in tuberculosis cases and the epidemiological trends in China: a causal impact analysis. *Infect*
546 *Drug Resist.* 2021;14:4641-55. doi: 10.2147/IDR.S337473.
- 547 23. Fei H, Yinyin X, Hui C, Ni W, Xin D, Wei C, et al. The impact of the COVID-19 epidemic on tuberculosis
548 control in China. *Lancet Reg Health West Pac.* 2020;3:100032. doi: 10.1016/j.lanwpc.2020.100032.
- 549 24. Maia CMF, Martelli DRB, Silveira D, Oliveira EA, Martelli Junior H. Tuberculosis in Brazil: the impact of the
550 COVID-19 pandemic. *J Bras Pneumol.* 2022;48(2):e20220082. doi: 10.36416/1806-3756/e20220082.
- 551 25. Gigante AR, Sousa M, Aguiar A, Pinto M, Gaio R, Duarte R. The impact of COVID-19 on the TB response:
552 data from the field. *Int J Tuberc Lung Dis.* 2021;25(9):769-71. doi: 10.5588/ijtld.21.0149.
- 553 26. Godoy P, Parrón I, Barrabeig I, Caylà JA, Clotet L, Follia N, et al. Impact of the COVID-19 pandemic on
554 contact tracing of patients with pulmonary tuberculosis. *European Journal of Public Health.*
555 2022;32(4):643-7. doi: 10.1093/eurpub/ckac031.
- 556 27. Golandaj JA. Pediatric TB detection in the era of COVID-19. *Indian J Tuberc.* 2022;69(1):104-8. doi:
557 10.1016/j.ijtb.2021.04.015.
- 558 28. Hasan T, Nguyen VN, Nguyen HB, Nguyen TA, Le HTT, Pham CD, et al. Retrospective Cohort Study of
559 Effects of the COVID-19 Pandemic on Tuberculosis Notifications, Vietnam, 2020. *Emerg Infect Dis.*
560 2022;28(3):684-92. doi: 10.3201/eid2803.211919.
- 561 29. Iyengar KP, Jain VK. Tuberculosis and COVID-19 in India- double trouble! *Indian J Tuberc.*
562 2020;67(4s):S175-6. doi: 10.1016/j.ijtb.2020.07.014.

- 563 30. Kadota JL, Reza TF, Nalugwa T, Kityamuwesi A, Nanyunja G, Kiwanuka N, et al. Impact of shelter-in-place
564 on TB case notifications and mortality during the COVID-19 pandemic. *Int J Tuberc Lung Dis*.
565 2020;24(11):1212-14. doi: 10.5588/ijtld.20.0626.
- 566 31. Komiya K, Yamasue M, Takahashi O. The COVID-19 pandemic and the true incidence of Tuberculosis in
567 Japan. *J Infect*. 2020;81(3):e24-e25. doi: 10.1016/j.jinf.2020.07.004.
- 568 32. Kwak N, Hwang S-S, Yim J-J. Effect of COVID-19 on tuberculosis notification, South Korea. *Emerg Infect Dis*.
569 2020;26(10):2506-8. doi: 10.3201/eid2610.202782.
- 570 33. Lebina L, Dube M, Hlongwane K, Brahmabatt H, Lala SG, Reubenson G, et al. Trends in paediatric
571 tuberculosis diagnoses in two South African hospitals early in the COVID-19 pandemic. *S. Afr. Med. J.*
572 2020;110(12):1149-51. doi: 10.7196/SAMJ.2020.v110i12.15386.
- 573 34. Lewer D, Mulchandani R, Roche A, Cosgrove C, Anderson C. Why has the incidence of tuberculosis not
574 reduced in London during the COVID-19 pandemic? *Lancet Respir Med*. 2022;10(3):231-3. doi:
575 10.1016/s2213-2600(22)00012-1.
- 576 35. Liu Q, Lu P, Shen Y, Li C, Wang J, Zhu L. Collateral impact of the coronavirus disease 2019 (COVID-19)
577 pandemic on tuberculosis control in Jiangsu Province, China. *Clin Infect Dis*. 2021;73(3):542-4. doi:
578 10.1093/cid/ciaa1289.
- 579 36. Martin-Hughes R, Vu L, Cheikh N, Kelly SL, Fraser-Hurt N, Shubber Z, et al. Impacts of COVID-19-related
580 service disruptions on TB incidence and deaths in Indonesia, Kyrgyzstan, Malawi, Mozambique, and Peru:
581 implications for national TB responses. *PLOS Glob Public Health*. 2022;2(3):e0000219. doi:
582 10.1371/journal.pgph.0000219.
- 583 37. McQuaid CF, Henrion MYR, Burke RM, MacPherson P, Nzawa-Soko R, Horton KC. Inequalities in the
584 impact of COVID-19-associated disruptions on tuberculosis diagnosis by age and sex in 45 high TB burden
585 countries. *BMC Med*. 2022;20(1):432. doi: 10.1186/s12916-022-02624-6.
- 586 38. McQuaid CF, McCreesh N, Read JM, Sumner T, Houben R, White RG, et al. The potential impact of COVID-
587 19-related disruption on tuberculosis burden. *Eur Respir J*. 2020;56(2):2001718. doi:
588 10.1183/13993003.01718-2020.

- 589 39. Migliori GB, Thong PM, Alffenaar JW. Country-specific lockdown measures in response to the COVID-19
590 pandemic and its impact on tuberculosis control: a global study. *J Bras Pneumol.* 2022;48(2):e20220087.
591 doi: 10.36416/1806-3756/e20220087.
- 592 40. Migliori GB, Thong PM, Alffenaar JW, Denholm J, Tadolini M, Alyaquobi F, et al. Gauging the impact of the
593 COVID-19 pandemic on tuberculosis services: a global study. *Eur Respir J.* 2021;58(5) doi:
594 10.1183/13993003.01786-2021.
- 595 41. Odume B, Falokun V, Chukwuogo O, Ogbudebe C, Useni S, Nwokoye N, et al. Impact of COVID-19 on TB
596 active case finding in Nigeria. *Public Health Action.* 2020;10(4):157-62. doi: 10.5588/pha.20.0037.
- 597 42. Ortiz-Martínez Y, Rodríguez-Morales AJ, Henao-Martínez AF. Decreased notification of TB cases during the
598 COVID-19 pandemic. *Int J Tuberc Lung Dis.* 2022;26(2):177-8. doi: 10.5588/ijtld.21.0651.
- 599 43. Ozdemir S, Oztomurcuk D, Oruc MA. Impact of the COVID-19 pandemic on tuberculosis patients and
600 tuberculosis control programs in Turkey, review and analysis. *Arch Public Health.* 2022;80(1):252. doi:
601 10.1186/s13690-022-01007-w.
- 602 44. Ranasinghe L, Achar J, Gröschel MI, Whittaker E, Dodd PJ, Seddon JA. Global impact of COVID-19 on
603 childhood tuberculosis: an analysis of notification data. *Lancet Glob Health.* 2022;10(12):e1774-81. doi:
604 10.1016/s2214-109x(22)00414-4.
- 605 45. Tok PSK, Kamarudin NA, Jamaludin M, Ab Razak MF, Ahmad MAS, Abu Bakar FA, et al. Effect of COVID-19
606 on tuberculosis notification in Johor Bahru, Malaysia. *Infect Dis.* 2022;54(3):235-7. doi:
607 10.1080/23744235.2021.2000636.
- 608 46. Wang X, He W, Lei J, Liu G, Huang F, Zhao Y. Impact of COVID-19 pandemic on pre-treatment delays,
609 detection, and clinical characteristics of tuberculosis patients in Ningxia Hui Autonomous Region, China.
610 *Front Public Health.* 2021;9:644536. doi: 10.3389/fpubh.2021.644536.
- 611 47. World Health Organization. Impact of the COVID-19 pandemic on TB detection and mortality in 2020.
612 Accessed from: [https://www.who.int/publications/m/item/impact-of-the-covid-19-pandemic-on-tb-](https://www.who.int/publications/m/item/impact-of-the-covid-19-pandemic-on-tb-detection-and-mortality-in-2020)
613 [detection-and-mortality-in-2020](https://www.who.int/publications/m/item/impact-of-the-covid-19-pandemic-on-tb-detection-and-mortality-in-2020) on May 9, 2023
- 614 48. Wu Z, Chen J, Xia Z, Pan Q, Yuan Z, Zhang W, et al. Impact of the COVID-19 pandemic on the detection of
615 TB in Shanghai, China. *Int J Tuberc Lung Dis.* 2020;24(10):1122-4. doi: 10.5588/ijtld.20.0539.

- 616 49. Xu C, Li T, Hu D, Zhang H, Zhao Y, Liu J. Predicted Impact of the COVID-19 responses on deaths of
617 tuberculosis - China, 2020. *China CDC Wkly.* 2021;3(2):21-4. doi: 10.46234/ccdcw2021.004.
- 618 50. Xu J, Wang Y, Liu F, Yang H. Changes of tuberculosis infection in mainland China before and after the
619 COVID-19 pandemic. *J Infect.* 2023;86(2):154-225. doi: 10.1016/j.jinf.2022.12.008.
- 620 51. Zamani S, Honarvar MR, Behnampour N, Sheikhy M, Sedaghat M, Ghaemi S, et al. Decline in TB incidence
621 during the COVID-19 pandemic. *Int J Tuberc Lung Dis.* 2021;25(12):1043-4. doi: 10.5588/ijtld.21.0548.
- 622 52. Burzynski J, Macaraig M, Nilsen D, Schluger NW. Transforming essential services for tuberculosis during
623 the COVID-19 pandemic: lessons from New York City. *Int J Tuberc Lung Dis.* 2020;24(7):735-6. doi:
624 10.5588/ijtld.20.0283.
- 625 53. Ruhwald M, Carmona S, Pai M. Learning from COVID-19 to reimagine tuberculosis diagnosis. *The Lancet*
626 *Microbe.* 2021;2(5):e169-70. doi: 10.1016/s2666-5247(21)00057-4.
- 627 54. Pai M, Kasaeva T, Swaminathan S. Covid-19's devastating effect on tuberculosis care—a path to recovery.
628 *N Engl J Med.* 2022;386(16):1490-3. doi: 10.1056/NEJMp2118145.
- 629 55. Tobing KL, Letelay AM, Senewe FP, Lolong DB, Pracoyo NE, Susanti L, et al. TB Active case-finding before
630 and during the Covid-19 pandemic. *Proceedings of the 1st International Conference for Health Research –*
631 *BRIN (ICHR 2022);* 2023:469-81.;2023:469-81.
- 632 56. Bardhan M, Hasan MM, Ray I, Sarkar A, Chahal P, Rackimuthu S, et al. Tuberculosis amidst COVID-19
633 pandemic in India: unspoken challenges and the way forward. *Trop Med Health.* 2021;49(1):84. doi:
634 10.1186/s41182-021-00377-1.
- 635 57. Di Gennaro F, Gualano G, Timelli L, Vittozzi P, Di Bari V, Libertone R, et al. Increase in tuberculosis
636 diagnostic delay during first wave of the COVID-19 pandemic: data from an Italian infectious disease
637 referral hospital. *Antibiotics (Basel).* 2021;10(3):272. doi: 10.3390/antibiotics10030272.
- 638 58. Diallo A, Combarry A, Veronese V, Dahourou DL, Ouédraogo S, Traoré IT, et al. Delays in TB diagnosis and
639 treatment initiation in Burkina Faso during the COVID-19 pandemic. *Trop Med Infect Dis.* 2022;7(9):232.
640 doi: 10.3390/tropicalmed7090237.

- 641 59. Hazra D, Chawla K, Shenoy VP, Pandey AK, S N. The aftermath of COVID-19 pandemic on the diagnosis of
642 TB at a tertiary care hospital in India. *J Infect Public Health*. 2021;14(8):1095-8. doi:
643 10.1016/j.jiph.2021.07.001.
- 644 60. Lakoh S, Jiba DF, Baldeh M, Adekanmbi O, Barrie U, Seisay AL, et al. Impact of COVID-19 on tuberculosis
645 case detection and treatment outcomes in Sierra Leone. *Trop Med Infect Dis*. 2021;6(3):154. doi:
646 10.3390/tropicalmed6030154.
- 647 61. Lestari T, Kamaludin, Lowbridge C, Kenangalem E, Poespoprodjo JR, Graham SM, et al. Impacts of
648 tuberculosis services strengthening and the COVID-19 pandemic on case detection and treatment
649 outcomes in Mimika District, Papua, Indonesia: 2014-2021. *PLOS Glob Public Health*. 2022;2(9):e0001114.
650 doi: 10.1371/journal.pgph.0001114.
- 651 62. Loh FK, Thong PM, Ong CWM. The crucial need for tuberculosis translational research in the time of
652 COVID-19. *Lancet Respir Med*. 2022;10(6):531-3. doi: 10.1016/s2213-2600(22)00099-6.
- 653 63. MacLean EL, Villa-Castillo L, Ruhwald M, Ugarte-Gil C, Pai M. Integrated testing for TB and COVID-19. *Med*
654 *(N Y)*. 2022;3(3):162-6. doi: 10.1016/j.medj.2022.02.002.
- 655 64. Malik AA, Safdar N, Chandir S, Khan U. Tuberculosis control and care in the era of COVID-19. *Health Policy*
656 *Plan*. 2020;35(8):1130-32. doi: 10.1093/heapol/czaa109.
- 657 65. Mohammed H, Oljira L, Roba KT, Yimer G, Fekadu A, Manyazewal T. Containment of COVID-19 in Ethiopia
658 and implications for tuberculosis care and research. *Infect Dis Poverty*. 2020;9(1):131. doi:
659 10.1186/s40249-020-00753-9.
- 660 66. Muñoz-Salazar R, Le T, Cuevas-Mota J, González-Fagoaga JE, Zapata-Garibay R, Ruiz-Tamayo PS, et al.
661 Impact of COVID-19 on tuberculosis detection and treatment in Baja California, México. *Front Public*
662 *Health*. 2022;10:921596. doi: 10.3389/fpubh.2022.921596.
- 663 67. Nalunjogi J, Mucching-Toscano S, Sibomana JP, Centis R, D'Ambrosio L, Alffenaar JW, et al. Impact of
664 COVID-19 on diagnosis of tuberculosis, multidrug-resistant tuberculosis, and on mortality in 11 countries
665 in Europe, Northern America, and Australia. A Global Tuberculosis Network study. *Int J Infect Dis*. *Int J*
666 *Infect Dis*. 2023;130(Suppl 1):S25-9. doi: 10.1016/j.ijid.2023.02.025.

- 667 68. Narita M, Hatt G, Toren KG. Narita M, Hatt G, Toren KG. Delayed tuberculosis diagnoses during the
668 coronavirus disease 2019 (COVID-19) pandemic in 2020—King County, Washington. *Clin Infect Dis*.
669 2021;73(Suppl 1):S74-6. doi: 10.1093/cid/ciab387.
- 670 69. Nikolayevskyy V, Holicka Y, van Soolingen D, van der Werf MJ, Ködmön C, Surkova E, et al. Impact of
671 COVID-19 on tuberculosis case detection and treatment outcomes in Sierra Leone. *Eur Respir J*.
672 2021;57(1):154. doi: 10.1183/13993003.03890-2020.
- 673 70. Santos VS, Allgayer MF, Kontogianni K, Rocha JE, Pimentel BJ, Amorim MTP, et al. Pooling of sputum
674 samples to increase tuberculosis diagnostic capacity in Brazil during the COVID-19 pandemic. *Int J Infect*
675 *Dis*. 2023;129:10-4. doi: 10.1016/j.ijid.2023.01.009.
- 676 71. Schiza V, Kruse M, Xiao Y, Kar S, Lovejoy K, Wrighton-Smith P, et al. Impact of the COVID-19 pandemic on
677 TB infection testing. *Int J Tuberc Lung Dis*. 2022;26(2):174-6. doi: 10.5588/ijtld.21.0628.
- 678 72. Tovar M, Aleta A, Sanz J, Moreno Y. Modelling the impact of COVID-19 on future tuberculosis burden.
679 *Commun Med (Lond)*. 2022;2:77. doi: 10.1038/s43856-022-00145-0.
- 680 73. Maurer FP, Shubladze N, Kalmambetova G, Felker I, Kuchukhidze G, Drobniewski F, et al. Impact of the
681 COVID-19 pandemic on tuberculosis national reference laboratory services in the WHO European Region,
682 March to November 2020. *Euro Surveill*. 2021;26(24):2100426. doi: 10.2807/1560-
683 7917.Es.2021.26.24.2100426.
- 684 74. Awasthi AK, Singh PK. Tuberculosis management in India during COVID-19 crisis. *J Public Health Policy*.
685 2021;42(1):185-9. doi: 10.1057/s41271-020-00265-8.
- 686 75. Apolisi I, Mema N, Tyeku N, Beko B, Memani B, Daniels J, et al. Supporting families with tuberculosis
687 during COVID-19 in Khayelithsa, South Africa. *Lancet Respir Med*. 2022;10(6):542-3. doi: 10.1016/s2213-
688 2600(22)00121-7.
- 689 76. Arega B, Negesso A, Taye B, Weldeyohans G, Bewket B, Negussie T, et al. Impact of COVID-19 pandemic
690 on TB prevention and care in Addis Ababa, Ethiopia: a retrospective database study. *BMJ Open*.
691 2022;12(2):e053290. doi: 10.1136/bmjopen-2021-053290.

- 692 77. Benade M, Long L, Meyer-Rath G, Miot J, Evans D, Tucker JM, et al. Reduction in initiations of drug-
693 sensitive tuberculosis treatment in South Africa during the COVID-19 pandemic: analysis of retrospective,
694 facility-level data. *PLOS Glob Public Health*. 2022;2(10):e0000559. doi: 10.1371/journal.pgph.0000559.
- 695 78. Caren GJ, Iskandar D, Pitaloka DAE, Abdulah R, Suwantika AA. COVID-19 pandemic disruption on the
696 management of tuberculosis treatment in Indonesia. *J Multidiscip Healthc*. 2022;15:175-83. doi:
697 10.2147/jmdh.S341130.
- 698 79. Chilot D, Woldeamanuel Y, Manyazewal T. Real-time impact of COVID-19 on clinical care and treatment of
699 patients with tuberculosis: a multicenter cross-sectional study in Addis Ababa, Ethiopia. *Ann Glob Health*.
700 2021;87(1):109. doi: 10.5334/aogh.3481.
- 701 80. Coutinho I, Alves LC, Werneck GL, Trajman A. The impact of the COVID-19 pandemic in tuberculosis
702 preventive treatment in Brazil: a retrospective cohort study using secondary data. *Lancet Reg Health Am*.
703 2023;19:100444. doi: 10.1016/j.lana.2023.100444.
- 704 81. Gandhi AP, Kathirvel S, Rehman T. Effect of COVID-19 lockdown on the pathway of care and treatment
705 outcome among patients with tuberculosis in a rural part of northern India: a community-based study. *J*
706 *Rural Med*. 2022;17(2):59-66. doi: 10.2185/jrm.2021-039.
- 707 82. Geric C, Saroufim M, Landsman D, Richard J, Benedetti A, Batt J, et al. Impact of COVID-19 on tuberculosis
708 prevention and treatment in Canada: a multicenter analysis of 10,833 patients. 2022;225(8):1317-20. doi:
709 10.1093/infdis/jiab608.
- 710 83. Jeong Y, Min J. Impact of COVID-19 pandemic on tuberculosis preventive services and their post-pandemic
711 recovery strategies: a rapid review of literature. *J Korean Med Sci*. 2023;38(5):e43. doi:
712 10.3346/jkms.2023.38.e43.
- 713 84. Louie JK, Agraz-Lara R, Romo L, Crespín F, Chen L, Graves S. Tuberculosis-associated hospitalizations and
714 deaths after COVID-19 shelter-in-place, San Francisco, California, USA. *Emerg Infect Dis*. 2021;27(8):2227-
715 9. doi: 10.3201/eid2708.210670.
- 716 85. Magro P, Formenti B, Marchese V. Impact of the SARS-CoV-2 epidemic on tuberculosis treatment
717 outcome in Northern Italy. *Eur Respir J*. 2020;56(4):2002665. doi: 10.1183/13993003.02665-2020.

- 718 86. Meneguim AC, Rebello L, Das M, Ravi S, Mathur T, Mankar S, et al. Adapting TB services during the COVID-
719 19 pandemic in Mumbai, India. *Int J Tuberc Lung Dis.* 2020;24(10):1119-21. doi: 10.5588/ijtld.20.0537.
- 720 87. Min J, Ko Y, Kim HW, Koo HK, Oh JY, Jeong YJ, et al. Increased healthcare delays in tuberculosis patients
721 during the first wave of COVID-19 pandemic in Korea: a nationwide cross-sectional study. *J Korean Med*
722 *Sci.* 2022;37(3):e20. doi: 10.3346/jkms.2022.37.e20.
- 723 88. Mohr-Holland E, Douglas-Jones B, Apolisi I. Tuberculosis preventive therapy for children and adolescents:
724 an emergency response to the COVID-19 pandemic. *Lancet Child Adolesc Health.* 2021;5(3):159-61. doi:
725 10.1016/S2352-4642(21)00003-1.
- 726 89. Namkoong H, Horita N, Ebina-Shibuya R. Concern over a COVID-19-related BCG shortage. *The*
727 *International Journal of Tuberculosis and Lung Disease.* 2020;24(6):642-3. doi: 10.5588/ijtld.20.0240.
- 728 90. Keshavjee S. Progress toward global tuberculosis elimination goals and opportunities for moving forward.
729 In: Biffl C, Liao J, Nicholson A, eds. *Innovations for tackling tuberculosis in the time of COVID-19:*
730 *proceedings of a workshop, 2022.* National Academies of Sciences, Engineering, and Medicine. The
731 National Academies Press, Washington, DC. Available from:
732 [https://nap.nationalacademies.org/catalog/26530/innovations-for-tackling-tuberculosis-in-the-time-of-](https://nap.nationalacademies.org/catalog/26530/innovations-for-tackling-tuberculosis-in-the-time-of-covid-19)
733 [covid-19.](https://nap.nationalacademies.org/catalog/26530/innovations-for-tackling-tuberculosis-in-the-time-of-covid-19)
- 734 91. Padmapriyadarsini C, Banurekha V, Arora VK. Challenges in TB control and the anticipated COVID-19 third
735 wave: Way forward. *Indian J Tuberc.* 2021;68(4):425-7. doi: 10.1016/j.ijtb.2021.07.014.
- 736 92. Rai DK, Kumar R, Pandey SK. Problems faced by tuberculosis patients during COVID-19 pandemic: urgent
737 need to intervene. *Indian J Tuberc.* 2020;67(4s):S173-4. doi: 10.1016/j.ijtb.2020.07.013.
- 738 93. Sahu S, Wandwalo E, Arinaminpathy N. Exploring the impact of the COVID-19 pandemic on tuberculosis
739 care and prevention. *J Pediatric Infect Dis Soc.* 2022;11(Suppl 3):S67-71. doi: 10.1093/jpids/piac102.
- 740 94. Shaikh N, Pelzer PT, Thyssen SM, Roy P, Harris RC, White RG. Impact of COVID-19 disruptions on global BCG
741 coverage and paediatric tb mortality: a modelling study. *Vaccines.* 2021;9(11):1228. doi:
742 10.3390/vaccines9111228.

- 743 95. Tiberi S, Vjecha MJ, Zumla A, Galvin J, Migliori GB, Zumla A. Accelerating development of new shorter TB
744 treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19
745 pandemic. *Int J Infect Dis.* 2021;113(Suppl 1):S96-9. doi: 10.1016/j.ijid.2021.02.067.
- 746 96. Abikoye TM. Collateral damage: the impact of the COVID-19 pandemic on the care of a patient with
747 tuberculous neuroretinitis in Lagos, Nigeria. *Pan Afr Med J.* 2020;35(Suppl 2):S135. doi:
748 10.11604/pamj.supp.2020.35.135.24691.
- 749 97. United Nations International Children's Emergency Fund. Bacillus Calmette-Guérin (BCG) vaccine supply
750 and demand update, UNICEF, Copenhagen, August 2019. Available from:
751 <https://www.unicef.org/supply/reports/bacillus-calmette-guérin-bcg-supply-and-demand-update>
- 752 98. Ritz N, Hanekom WA, Robins-Browne R, Britton WJ, Curtis N. Influence of BCG vaccine strain on the
753 immune response and protection against tuberculosis. *FEMS Microbiol Rev.* 2008;32(5):821-41. doi:
754 10.1111/j.1574-6976.2008.00118.x.
- 755 99. Pittet LF, Messina NL, Orsini F, Moore CL, Abruzzo V, Barry S, et al. Randomized Trial of BCG Vaccine to
756 Protect against Covid-19 in Health Care Workers. *N Engl J Med.* 2023;388(17):1582-96. doi:
757 10.1056/NEJMoa2212616.
- 758 100. Cardenas-Escalante J, Fernandez-Saucedo J, Cubas WS. Impact of the COVID-19 pandemic on tuberculosis
759 in Peru: Are we forgetting anyone? *Enferm Infecc Microbiol Clin (Engl Ed).* 2022;40(1):46-7. doi:
760 10.1016/j.eimce.2021.07.008.
- 761 101. Fekadu G, Jiang X, Yao J, You JHS. Cost-effectiveness of video-observed therapy for ambulatory
762 management of active tuberculosis during the COVID-19 pandemic in a high-income country. *Int J Infect*
763 *Dis.* 2021;113:271-8. doi: 10.1016/j.ijid.2021.10.029.
- 764 102. Klinton JS, Heitkamp P, Rashid A, Faleye BO, Win Htat H, Hussain H, et al. One year of COVID-19 and its
765 impact on private provider engagement for TB: A rapid assessment of intermediary NGOs in seven high TB
766 burden countries. *J Clin Tuberc Other Mycobact Dis.* 2021;25:100277. doi: 10.1016/j.jctube.2021.100277.
- 767 103. Koura KG, Harries AD, Fujiwara PI, Dlodlo RA, Sansan EK, Kamper B, et al. COVID-19 in Africa: community
768 and digital technologies for tuberculosis management. *Int J Tuberc Lung Dis.* 2020;24(8):863-5. doi:
769 10.5588/ijtld.20.0412.

- 770 104. Kumwichar P, Chongsuvivatwong V, Prappre T. Video-observed therapy with a notification system for
771 improving the monitoring of tuberculosis treatment in Thailand: usability study. *JMIR Form Res.*
772 2022;6(5):e35994. doi: 10.2196/35994.
- 773 105. Lippincott CK, Perry A, Munk E, Maltas G, Shah M. Tuberculosis treatment adherence in the era of COVID-
774 19. *BMC Infect Dis.* 2022;22(1):800. doi: 10.1186/s12879-022-07787-4.
- 775 106. Watts K, McKeown A, Denholm J, Baker AM. Responding to COVID-19: adjusting TB services in a low-
776 burden setting. *Int J Tuberc Lung Dis.* 2020;24(8):866-9. doi: 10.5588/ijtld.20.0337.
- 777 107. Calnan M, Moran A, Jassim AlMossawi H. Maintaining essential tuberculosis services during the COVID-19
778 pandemic, Philippines. *Bull World Health Organ.* 2022;100(2):127-34. doi: 10.2471/blt.21.286807.
- 779 108. Visca D, Tiberi S, Pontali E, Spanevello A, Migliori, GB. Tuberculosis in the time of COVID-19: quality of life
780 and digital innovation. *Eur Respir J.* 2020;56(2):2001998. doi: 10.1183/13993003.01998-2020.
- 781 109. Bachina P, Lippincott CK, Perry A, Munk E, Maltas G, Bohr R, et al. Programmatic adoption and
782 implementation of video-observed therapy in Minnesota: prospective observational cohort study. *JMIR*
783 *Form Res.* 2022;6(8):e38247. doi: 10.2196/38247.
- 784 110. Migliori GB, Thong PM, Akkerman O, Alffenaar JW, Álvarez-Navascués F, Assao-Neino MM, et al.
785 Worldwide effects of coronavirus disease pandemic on tuberculosis services, January-April 2020. *Emerg*
786 *Infect Dis.* 2020;26(11):2709-12. doi: 10.3201/eid2611.203163.
- 787 111. Bhatia V, Mandal PP, Satyanarayana S, Aditama TY, Sharma M. Mitigating the impact of the COVID-19
788 pandemic on progress towards ending tuberculosis in the WHO South-East Asia Region. *WHO South East*
789 *Asia J Public Health.* 2020;9(2):95-9. doi: 10.4103/2224-3151.294300.
- 790 112. Singh PK. Strengthening social protection for TB patients: Lessons from COVID-19. *PLOS Global Public*
791 *Health.* 2022;2(8):e0000950. doi: 10.1371/journal.pgph.0000950.
- 792 113. Chatterjee S, Das P, Vassall A. Impact of COVID-19 restrictive measures on income and health service
793 utilization of tuberculosis patients in India. *BMC Infect Dis.* 2022;22(1):711. doi: 10.1186/s12879-022-
794 07681-z.
- 795 114. Bhargava A, Shewade HD. The potential impact of the COVID-19 response related lockdown on TB
796 incidence and mortality in India. *Indian J Tuberc.* 2020;67(4s):S139-46. doi: 10.1016/j.ijtb.2020.07.004.

- 797 115. Saunders MJ, Evans CA. COVID-19, tuberculosis and poverty: preventing a perfect storm. *Eur Respir J*.
798 2020;56(1):2001348. doi: 10.1183/13993003.01348-2020.
- 799 116. George S, Paranjpe A, Nagesh P, Saalim M. Barriers to treatment adherence for female tuberculosis (TB)
800 patients during the COVID-19 pandemic: qualitative evidence from front-line TB interventions in
801 Bengaluru City, India. *Indian J Public Health*. 2022;66(1):38-44. doi: 10.4103/ijph.ijph_1146_21.
- 802 117. Khan FMA, Kazmi Z, Hasan MM. Resurgence of tuberculosis amid COVID-19 in Peru: associated risk
803 factors and recommendations. 2021;36(6):2441-2445. doi: 10.1002/hpm.3291.
- 804 118. Knipper M, Sedas AC, Keshavjee S, Abbara A, Almhawish N, Alashawi H, et al. The need for protecting and
805 enhancing TB health policies and services for forcibly displaced and migrant populations during the
806 ongoing COVID-19 pandemic. *Int J Infect Dis*. 2021;113 Suppl 1:S22-7. doi: 10.1016/j.ijid.2021.03.047.
- 807 119. Louie JK, Reid M, Stella J, Agraz-Lara R, Graves S, Chen L, et al. A decrease in tuberculosis evaluations and
808 diagnoses during the COVID-19 pandemic. *Int J Tuberc Lung Dis*. 2020;24(8):860-2. doi:
809 10.5588/ijtld.20.0364.
- 810 120. McQuaid CF, Vassall A, Cohen T, Fiekert K, White RG. The impact of COVID-19 on TB: a review of the data.
811 *Int J Tuberc Lung Dis*. 2021;25(6):436-46. doi: 10.5588/ijtld.21.0148.
- 812 121. Ryckman T, Robsky K, Cilloni L. Ending tuberculosis in a post-COVID-19 world: a person-centred, equity-
813 oriented approach. *Lancet Infect Dis*. 2023;23(2):e59-66. doi: 10.1016/S1473-3099(22)00500-X.
- 814 122. Shrinivasan R, Rane S, Pai M. India's syndemic of tuberculosis and COVID-19. *BMJ Glob Health*. 2020;5(11)
815 doi: 10.1136/bmjgh-2020-003979.
- 816 123. Souza LLL, Santos FLd, Crispim JdA, Fiorati RC, Dias S, Bruce ATI, et al. Causes of multidrug-resistant
817 tuberculosis from the perspectives of health providers: challenges and strategies for adherence to
818 treatment during the COVID-19 pandemic in Brazil. *BMC Health Serv Res*. 2021;21(1):1-10. doi:
819 10.1186/s12913-021-07057-0.
- 820 124. Vanleeuw L, Zembe-Mkabile W, Atkins S. Falling through the cracks: Increased vulnerability and limited
821 social assistance for TB patients and their households during COVID-19 in Cape Town, South Africa. *PLOS*
822 *Glob Public Health*. 2022;2(7):e0000708. doi: 10.1371/journal.pgph.0000708.

- 823 125. Zumla A, Chakaya J, Khan M, Fatima R, Wejse C, Al-Abri S, et al. 'The Clock is Ticking'—and the world is
824 running out of time to deliver the United Nations General Assembly commitments to End TB due to the
825 COVID-19 pandemic. *Int J Infect Dis.* 2021;113(Suppl 1):S1-6. doi: 10.1016/j.ijid.2021.03.046.
- 826 126. Mannan S, Oga-Omenka C, Soman ThekkePurakkal A, Huria L, Kalra A, Gandhi R, et al. Adaptations to the
827 first wave of the COVID-19 pandemic by private sector tuberculosis care providers in India. *J Clin Tuberc
828 Other Mycobact Dis.* 2022;28:100327. doi: 10.1016/j.jctube.2022.100327.
- 829 127. Awan HA, Sahito AM, Sukaina M, Khatri G, Waheed S, Sohail F, et al. Tuberculosis amidst COVID-19 in
830 Pakistan: a massive threat of overlapping crises for the fragile healthcare systems. *Epidemiol Infect.*
831 2022;150:e41. doi: 10.1017/s0950268822000358.
- 832 128. Cox V, Wilkinson L, Grimsrud A, Hughes J, Reuter A, Conradie F, et al. Critical changes to services for TB
833 patients during the COVID-19 pandemic. *Int J Tuberc Lung Dis.* 2020;24(5):542-4. doi:
834 10.5588/ijtld.20.0205.
- 835 129. Driessche KV, Mahlobo PZ, Venter R. Face masks in the post-COVID-19 era: a silver lining for the damaged
836 tuberculosis public health response? *Lancet Respir Med.* 2021;9(4):340-342. doi: 10.1016/S2213-
837 2600(21)00020-5.
- 838 130. Jain VK, Iyengar KP, Samy DA, Vaishya R. Tuberculosis in the era of COVID-19 in India. *Diabetes Metab
839 Syndr.* 2020;14(5):1439-43. doi: 10.1016/j.dsx.2020.07.034.
- 840 131. Jamal WZ, Habib S, Khowaja S, Safdar N, Zaidi SMA. COVID-19: ensuring continuity of TB services in the
841 private sector. *Int J Tuberc Lung Dis.* 2020;24(8):870-2. doi: 10.5588/ijtld.20.0400.
- 842 132. Marti M, Zürcher K, Enane LA, Diero L, Marcy O, Tiendrebeogo T, et al. Impact of the COVID-19 pandemic
843 on TB services at ART programmes in low- and middle-income countries: a multi-cohort survey. *J Int AIDS
844 Soc.* 2022;25(10):e26018. doi: 10.1002/jia2.26018.
- 845 133. Masina HV, Lin IF, Chien LY. The Impact of the COVID-19 pandemic on tuberculosis case notification and
846 treatment outcomes in Eswatini. *Int J Public Health.* 2022;67:1605225. doi: 10.3389/ijph.2022.1605225.
- 847 134. Andom AT, Fejfar D, Yuen CM, Ndayizigiye M, Mugunga JC, Mukherjee JS. The impact of COVID-19 on
848 tuberculosis program performance in the Kingdom of Lesotho. *Trop Med Infect Dis.* 2023;8(3):165. doi:
849 10.3390/tropicalmed8030165.

- 850 135. Berra TZ, Ramos ACV, Alves YM, Tavares RBV, Tartaro AF, Nascimento MCD, et al. Impact of COVID-19 on
851 tuberculosis indicators in Brazil: a time series and spatial analysis study. *Trop Med Infect Dis.*
852 2022;7(9):247. doi: 10.3390/tropicalmed7090247.
- 853 136. Chiang CY, Islam T, Xu C, Chinnayah T, Garfin AMC, Rahevar K, et al. The impact of COVID-19 and the
854 restoration of tuberculosis services in the Western Pacific Region. *Eur Respir J.* 2020;56(4):2003054. doi:
855 10.1183/13993003.03054-2020.
- 856 137. Dlangalala T, Musekiwa A, Brits A, Maluleke K, Jaya ZN, Kgarosi K, et al. . Evidence of TB services at
857 primary healthcare level during COVID-19: a scoping review. *Diagnostics (Basel).* 2021;11(12):2221. doi:
858 10.3390/diagnostics11122221.
- 859 138. Fuady A, Houweling TAJ, Richardus JH. COVID-19 and Tuberculosis-Related Catastrophic Costs. *Am J Trop*
860 *Med Hyg.* 2020;104(2):436-40. doi: 10.4269/ajtmh.20-1125.
- 861 139. Khan AW, Khan B, Shah SK, Kazi GN, Quadir A, Ghafoor A, et al. The impact of covid-19 on TB care in
862 Pakistan during 2020. *Pak J Public Health.* 2022;12(1):8-11. doi: 10.32413/pjph.v12i1.997.
- 863 140. Khobragade RN, Kelkar RU, Sunilkumar M, Cency B, Murthy N, Surendran D, et al. Health system
864 resilience: ensuring TB services during COVID-19 pandemic in Kerala, India. *Indian J Tuberc.*
865 2022;69(4):427-31. doi: 10.1016/j.ijtb.2021.10.004.
- 866 141. Kim B, Kang YA, Lee J. Heterogeneous impact of Covid-19 response on tuberculosis burden by age group.
867 *Sci Rep.* 2022;12(1):13773. doi: 10.1038/s41598-022-18135-6.
- 868 142. Klinton JS, Oga-Omenka C, Heitkamp P. TB and COVID - Public and private health sectors adapt to a new
869 reality. *J Clin Tuberc Other Mycobact Dis.* 2020;21:100199. doi: 10.1016/j.jctube.2020.100199.
- 870 143. Manhiça I, Augusto O, Sherr K, Cowan J, Cuco RM, Agostinho S, et al. COVID-19-related healthcare
871 impacts: an uncontrolled, segmented time-series analysis of tuberculosis diagnosis services in
872 Mozambique, 2017-2020. *BMJ Glob Health.* 2022;7(4):e007878. doi: 10.1136/bmjgh-2021-007878.
- 873 144. Mihika FA, Jubayer Biswas MAA, Khan MMH, Islam SS, Haque MA, Banu S, et al. The effect of the COVID-
874 19 pandemic on pulmonary tuberculosis control in the selected Upazila health complexes of Dhaka
875 Division, Bangladesh. *Trop Med Infect Dis.* 2022;7(11):385. doi: 10.3390/tropicalmed7110385.

- 876 145. Min J, Kim HW, Koo HK, Ko Y, Oh JY, Kim J, et al. Impact of COVID-19 pandemic on the National PPM
877 Tuberculosis Control Project in Korea: the Korean PPM Monitoring Database between July 2019 and June
878 2020. *J Korean Med Sci.* 2020;35(43):e388. doi: 10.3346/jkms.2020.35.e388.
- 879 146. Nhari LG, Dzobo M, Chitungo I, Denhere K, Musuka G, Dzinamarira T. Implementing effective TB
880 prevention and treatment programmes in the COVID-19 era in Zimbabwe. A call for innovative
881 differentiated service delivery models. *Public Health Pract (Oxf).* 2020;1:100058. doi:
882 10.1016/j.puhip.2020.100058.
- 883 147. Oga-Omenka C, Sassi A, Vasquez NA, Baruwa E, Rosapep L, Daniels B, et al. Tuberculosis service
884 disruptions and adaptations during the first year of the COVID-19 pandemic in the private health sector of
885 two urban settings in Nigeria-A mixed methods study. *PLOS Glob Public Health.* 2023;3(3):e0001618. doi:
886 10.1371/journal.pgph.0001618.
- 887 148. Petersen E, Seif Al-Abr S, Chakaya J, Goletti D, Parolina L, Wejse C, et al. World TB Day 2022: Revamping
888 and reshaping global TB control programs by advancing lessons learnt from the COVID-19 pandemic. *Int J*
889 *Infect Dis.* 2022;124(Suppl 1):S1-3. doi: 10.1016/j.ijid.2022.02.057.
- 890 149. Reid MJA, Silva S, Arinaminpathy N, Goosby E. Building a tuberculosis-free world while responding to the
891 COVID-19 pandemic. *Lancet.* 2020;396:1312-13. doi: 10.1016/S0140-6736(20)32138-3.
- 892 150. Tran CH, Moore BK, Pathmanathan I, Lungu P, Shah NS, Oboho I, et al. Tuberculosis treatment within
893 differentiated service delivery models in global HIV/TB programming. *J Int AIDS Soc.* 2021;24(Suppl
894 6):e25809. doi: 10.1002/jia2.25809.
- 895 151. van Rensburg AJ, Petersen I, Awotiwon A, Bachmann MO, Curran R, Murdoch J, et al. Applying learning
896 health systems thinking in codeveloping integrated tuberculosis interventions in the contexts of COVID-
897 19. *BMJ Glob Health.* 2022;7(10):e009567. doi: 10.1136/bmjgh-2022-009567.
- 898 152. Cronin AM, Railey S, Fortune D, Wegener DH, Davis JB. Notes from the field: effects of the COVID-19
899 response on tuberculosis prevention and control efforts - United States, March-April 2020. *MMWR Morb*
900 *Mortal Wkly Rep.* 2020;69(29):971-2. doi: 10.15585/mmwr.mm6929a4.

- 901 153. Bouaddi O, Hasan MM, Sahito AM, Shah PA, Mohammed AZA, Essar MY. Tuberculosis in the middle of
902 COVID-19 in Morocco: efforts, challenges and recommendations. *Trop Med Health*. 2021;49(1):98. doi:
903 10.1186/s41182-021-00388-y.
- 904 154. Roberts T, Sahu S, Malar J, Abdullaev T, Vandeveldel W, Pillay YG, et al. Turning threats into opportunities:
905 how to implement and advance quality TB services for people with HIV during the COVID-19 pandemic
906 and beyond. *J Int AIDS Soc*. 2021;24(4):e25696. doi: 10.1002/jia2.25696.
- 907 155. Yadav P, Vohra C, Gopalakrishnan M, Garg MK. Integrating health planning and primary care
908 infrastructure for COVID-19 and tuberculosis care in India: challenges and opportunities. *Int J Health Plann*
909 *Manage*. 2022;37(2):632-42. doi: 10.1002/hpm.3393.
- 910 156. Ruiz-Grosso P, Cachay R, De La Flor A, Schwalb A, Ugarte-Gil C. Association between tuberculosis and
911 depression on negative outcomes of tuberculosis treatment: A systematic review and meta-analysis. *PLOS*
912 *ONE*. 2020;15(1):e0227472. doi: 10.1371/journal.pone.0227472.
- 913 157. Loveday M, Cox H, Evans D, Furin J, Ndjeka N, Osman M, et al. Opportunities from a new disease for an
914 old threat: Extending COVID-19 efforts to address tuberculosis in South Africa. *S Afr Med J*.
915 2020;110(12):1160-7. doi: 10.7196/SAMJ.2020.v110i12.15126.
- 916 158. Ferrer JP, Suzuki S, Alvarez C, Berido C, Caballero M, Caraig B, et al. Experiences, challenges and looking to
917 the future in a clinical tuberculosis cohort in the time of COVID-19 in the Philippines. *Trans R Soc Trop*
918 *Med Hyg*. 2021;115(6):579-82. doi: 10.1093/trstmh/trab025.
- 919 159. Malik AA, Hussain H, Maniar R, Safdar N, Mohiuddin A, Riaz N, et al. Integrated tuberculosis and COVID-19
920 activities in Karachi and tuberculosis case notifications. *Trop Med Infect Dis*. 2022;7(1):12. doi:
921 10.3390/tropicalmed7010012.
- 922 160. Zimmer AJ, Heitkamp P, Malar J, Dantas C, O'Brien K, Pandita A, et al. Facility-based directly observed
923 therapy (DOT) for tuberculosis during COVID-19: a community perspective. *J Clin Tuberc Other Mycobact*
924 *Dis*. 2021;24:100248. doi: <https://doi.org/10.1016/j.jctube.2021.100248>.
- 925 161. Sunjaya DK, Paskaria C, Pramayanti M, Herawati DMD, Parwati I. The magnitude of anxiety and depressive
926 symptoms among tuberculosis patients in community health centers setting during the peak of COVID-19
927 pandemic. *J Multidiscip Healthc*. 2022;15:755-64. doi: 10.2147/jmdh.S359530.

- 928 162. ACTION Global Health Advocacy Partnership et al. The impact of COVID-19 on the TB epidemic: a
929 community perspective, 2020. Accessed from: <https://spark.adobe.com/page/xJ7pygvhrlAqW/>
- 930 163. Mandal A, Verma AK, Kar SK, Bajpai J, Kant S, Kumar S, et al. A cross-sectional study to determine the
931 psychological distress among pulmonary tuberculosis patients during COVID-19 pandemic. *Monaldi Arch*
932 *Chest Dis.* 2022;93(1) doi: 10.4081/monaldi.2022.2255.
- 933 164. Millones AK, Lecca L, Acosta D, Campos H, Del Águila-Rojas E, Farroñay S, et al. The impact of the COVID-
934 19 pandemic on patients' experiences obtaining a tuberculosis diagnosis in Peru: a mixed-methods study.
935 *BMC Infect Dis.* 2022;22(1):829. doi: 10.1186/s12879-022-07832-2.
- 936 165. Santos FLD, Souza LLL, Bruce ATI, Crispim JA, Arroyo LH, Ramos ACV, et al. Patients' perceptions regarding
937 multidrug-resistant tuberculosis and barriers to seeking care in a priority city in Brazil during COVID-19
938 pandemic: A qualitative study. *PLoS One.* 2021;16(4):e0249822. doi: 10.1371/journal.pone.0249822.
- 939 166. Tinoco EM, Vasconcelos A, Alves F, Duarte R. Impact of COVID-19 on extrapulmonary TB and the benefit
940 of decentralised TB services. *Int J Tuberc Lung Dis.* 2022;26(2):178-80. doi: 10.5588/ijtld.21.0675.
- 941 167. Togun T, Kampmann B, Stoker NG, Lipman M. Anticipating the impact of the COVID-19 pandemic on TB
942 patients and TB control programmes. *Ann Clin Microbiol Antimicrob.* 2020;19(1):21. doi: 10.1186/s12941-
943 020-00363-1.
- 944 168. Zhang G, Yu Y, Zhang W, Shang J, Chen S, Pang X, et al. Influence of COVID-19 for delaying the diagnosis
945 and treatment of pulmonary tuberculosis-Tianjin, China. *Front Public Health.* 2022;10:937844. doi:
946 10.3389/fpubh.2022.937844.
- 947 169. Mwamba C, Kerkhoff AD, Kagujje M, Lungu P, Muyoyeta M, Sharma A. Diagnosed with TB in the era of
948 COVID-19: patient perspectives in Zambia. *Public Health Action.* 2020;10(4):141-6. doi:
949 10.5588/pha.20.0053.
- 950 170. Beyene NW, Sitotaw AL, Tegegn B, Bobosha K. The impact of COVID-19 on the tuberculosis control
951 activities in Addis Ababa. *Pan Afr Med J.* 2021;38:243. doi: 10.11604/pamj.2021.38.243.27132.
- 952 171. Buonsenso D, Iodice F, Sorba Biala J, Goletti D. COVID-19 effects on tuberculosis care in Sierra Leone.
953 *Pulmonology.* 2021;27(1):67-9. doi: 10.1016/j.pulmoe.2020.05.013.

- 954 172. Fatima R, Akhtar N, Yaqoob A, Harries AD, Khan MS. Building better tuberculosis control systems in a post-
955 COVID world: learning from Pakistan during the COVID-19 pandemic. *Int J Infect Dis.* 2021;113(Suppl
956 1):S88-90. doi: 10.1016/j.ijid.2021.03.026.
- 957 173. Islam M. Extensively drug-resistant tuberculosis in the time of COVID-19-How has the landscape changed
958 for Pakistan? *Disaster Med Public Health Prep.* 2020;14(4):e9-10. doi: 10.1017/dmp.2020.230.
- 959 174. Kumar P, Goyal JP. Tuberculosis during Covid-19 pandemic: challenges and opportunities. *Indian Pediatr.*
960 2020;57(11):1082. doi: 10.1007/s13312-020-2047-8.
- 961 175. Maroof M, Pamei G, Bhatt M, Awasthi S, Bahuguna SC, Singh P. Drug adherence to anti-tubercular
962 treatment during COVID-19 lockdown in Haldwani block of Nainital district. *Indian J Community Health.*
963 2022;34(4):535-41. doi: 10.47203/IJCH.2022.v34i04.016.
- 964 176. Oga-Omenka C, Tseja-Akinrin A, Boffa J, Heitkamp P, Pai M, Zarowsky C. Commentary: Lessons from the
965 COVID-19 global health response to inform TB case finding. *Healthc (Amst).* 2021;9(2):100487. doi:
966 10.1016/j.hjdsi.2020.100487.
- 967 177. Soko RN, Burke RM, Feasey HRA, Sibande W, Nliwasa M, Henrion MYR, et al. Effects of coronavirus
968 disease pandemic on tuberculosis notifications, Malawi. *Emerg Infect Dis.* 2021;27(7):1831-9. doi:
969 10.3201/eid2707.210557.
- 970 178. Uwishema O, Badri R, Onyeaka H, Okereke M, Akhtar S, Mhanna M, et al. Fighting tuberculosis in Africa:
971 the current situation amidst the COVID-19 pandemic. *Disaster Med Public Health Prep.* 2022;June 8:1-3.
972 doi: 10.1017/dmp.2022.142.
- 973 179. Zimmer AJ, Klinton JS, Oga-Omenka C. Tuberculosis in times of COVID-19. *J Epidemiol Community Health.*
974 2022;76(3):310-6. doi: 10.1136/jech-2021-217529.
- 975 180. Dheda K, Perumal T, Moultrie H, Perumal R, Esmail A, Scott AJ, et al. The intersecting pandemics of
976 tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective
977 interventions. *Lancet Respir Med.* 2022;10(6):603-22. doi: 10.1016/s2213-2600(22)00092-3.
- 978 181. Nkereuwem O, Nkereuwem E, Fiogbe A, Usoroh EE, Sillah AK, Owolabi O, et al. Exploring the perspectives
979 of members of international tuberculosis control and research networks on the impact of COVID-19 on

- 980 tuberculosis services: a cross sectional survey. *BMC Health Serv Res.* 2021;21(1):798. doi:
981 10.1186/s12913-021-06852-z.
- 982 182. Chapman HJ, Veras-Estévez BA. Lessons learned during the COVID-19 pandemic to strengthen tb infection
983 control: a rapid review. *Glob Health Sci Pract.* 2021;9(4):964-77. doi: 10.9745/ghsp-d-21-00368.
- 984 183. Anigbo AR, Gambhir L. Two years of the pandemic: Impact of COVID-19 on tuberculosis management in
985 Nigeria. *J Appl Pharm Sci.* 2022;12(8):001-008. doi: 10.7324/japs.2022.120801.
- 986 184. Chen H, Zhang K. Insight into the impact of the COVID-19 epidemic on tuberculosis burden in China. *Eur*
987 *Respir J.* 2020;56(3):2002710. doi: 10.1183/13993003.02710-2020.
- 988 185. Lipman M, McQuaid CF, Abubakar I, Khan M, Kranzer K, McHugh TD, et al. The impact of COVID-19 on
989 global tuberculosis control. *Indian J Med Res.* 2021;153(4):404-8. doi: 10.4103/ijmr.IJMR_326_21.
- 990 186. Lungu PS, Kerkhoff AD, Muyoyeta M, Kasapo CC, Nyangu S, Kagujje M, et al. Interrupted time-series
991 analysis of active case-finding for tuberculosis during the COVID-19 pandemic, Zambia. *Bull World Health*
992 *Organ.* 2022;100(3):205-15. doi: 10.2471/blt.21.286109.
- 993 187. Rodrigues I, Aguiar A, Migliori GB, Duarte R. Impact of the COVID-19 pandemic on tuberculosis services.
994 *Pulmonology.* 2022;28(3):210-9. doi: 10.1016/j.pulmoe.2022.01.015.
- 995 188. Tale S, Meitei Soibam P. Care of tuberculosis patients in the times of COVID-19. *Indian J Tuberc.*
996 2021;68(2):285-6. doi: 10.1016/j.ijtb.2020.09.004.
- 997 189. Wingfield T, Karmadwala F, MacPherson P, Millington KA, Walker NF, Cuevas LE, et al. Challenges and
998 opportunities to end tuberculosis in the COVID-19 era. *Lancet Respir Med.* 2021;9(6):556-8. doi:
999 10.1016/s2213-2600(21)00161-2.
- 1000 190. Shahnavazi M, Rigi F, Heydarikhayat N. Adherence to the treatment and influencing factors in patients
1001 with tuberculosis during the Covid-19 pandemic: a mixed method study. *Health Educ Health Promot.*
1002 2022;10(4):633-42.

1003

1004 SUPPORTING INFORMATION

1005 **S1. Fig. 1. This is the legend for Figure 1. Scoping Review Schema (Courtesy of COVIDENCE)**

1006 **S1. Fig. 2. Ten Themes Characterizing the Global Impact of COVID-19 on TB**

1007 **S2. Appendices**

1008 **1. Appendix 1. Scoping Review Protocol**

1009 **2. Appendix 2: Prisma ScR Checklist**


1010 **3. Appendix 3. Thematic Categorization of Publication**


1011 **4. Appendix 4. Policy Recommendations Derived from the Ten Principal Themes**

1012 **Highlighted in the Scoping Review of the Global Impact of COVID-19 on TB**

1013

1014





Figure